Navigation Links
New treatment hope for prostate cancer
Date:2/6/2009

Scientists at Melbourne's Burnet Institute have developed a potential new treatment for patients with prostate cancer. An article, which described the invention, has recently been published in the prestigious international journal The Journal of Clinical Investigation.

Head of the Burnet Institute's Cancer Immunotherapy Laboratory, Associate Professor Pei Xiang Xing said his group has produced a monoclonal antibody to a unique tumour marker for the treatment of prostate cancer. The monoclonal antibody is directed at cancer-producing cells carrying the specific molecule known as PIM-1, which is responsible for cell survival, proliferation and differentiation. Over-expression of PIM-1 plays a critical role in the development, progression and metastasis of prostate cancer and other cancers such as leukaemia. The monoclonal antibody significantly inhibited cancer cell growth when used in laboratory models of prostate cancer.

Professor Xing's group demonstrated that the monoclonal antibody binds to PIM-1 present in cancer cells and creates a chain of events leading to the death of the cells. In particular, the therapeutic effect was improved by combination of the antibody with other drugs currently used to treat prostate cancer.

Prostate cancer is one of the most frequently diagnosed invasive cancers and the third leading cause of death in men worldwide. More than 3,000 men die each year from prostate cancer, equal to the number of women who die from breast cancer; and more than 18,000 new cases are diagnosed in Australia each year. A new strategy to treat prostate cancer is urgently needed as there is no efficient method to treat advanced prostate cancer.

Director of the Burnet Institute, Professor Brendan Crabb said that while the therapy was still in its early days this was the first time that researchers had found a treatment that targeted prostate cancer cells with a specific antibody to PIM-1 and which resulted in t
'/>"/>

Contact: Tracy Routledge
tracy@burnet.edu.au
61-392-822-240
Research Australia
Source:Eurekalert

Page: 1 2

Related medicine news :

1. New treatment effective in counteracting cocaine-induced symptoms
2. New treatment boosts muscle function in myasthenia gravis
3. Broad-based group of physicians calls for improvement in stroke treatment
4. Cranberry Could Juice Up Ovarian Cancer Treatment
5. Non-medicinal treatment touted for pre-schoolers with ADHD
6. Nonmedicinal treatment touted for preschoolers with ADHD
7. U of M study: Early treatment can reverse heart damage
8. Biologic treatment for rheumatoid arthritis and the risk of cancer
9. New Treatment Explored for Cluster Headaches
10. Thailand: Partners Open Free AIDS Treatment Clinic in Renowned AIDS Temple in Lop Buri
11. 4-Star Gen. Barry Mccaffrey, Former U.S. Drug Czar, to Keynote Recovery Happens! Rally for Treatment: Wed., Sept. 5, 11 Am, State Capitol West Steps, Sacramento
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/5/2015)... ... August 05, 2015 , ... Hotze ... industry, is pleased to announce that it has added Electronic Beam Computed Tomography ... The scanner will be used primarily for conducting coronary artery scans and ...
(Date:8/5/2015)... ... ... the makers of the nation’s leading line of recovery drinks, has answered consumers’ calls once ... brew is smooth, rich and ready to travel, in three flavors. It tastes awesome because ... need milk and sugar to taste great like other traditional ready to drink coffees. ...
(Date:8/5/2015)... ... August 05, 2015 , ... Optimized Care Network (OCN) will join providers ... provide more patient choice during the first-ever Convenient Healthcare and Pharmacy Collaborative, Aug. 6-7. ... the challenges confronting retail clinics, how to expand their role and future trends in ...
(Date:8/5/2015)... ... 05, 2015 , ... i2i Systems announces the appointment of ... Systems team during a period of growth and platform expansion, driven by the ... to new shared-risk models that support enhanced clinical and financial outcomes and profitable ...
(Date:8/5/2015)... ... 05, 2015 , ... "Art de Toilettes" , It all ... suggest ideas to add some fun and visual interest to the company lobby. ... transform toilets into works of art. Renew Life makes natural digestive care supplements ...
Breaking Medicine News(10 mins):Health News:Hotze Health & Wellness Center Adds EBCT Imaging Services to Preventative Screening Program 2Health News:Hotze Health & Wellness Center Adds EBCT Imaging Services to Preventative Screening Program 3Health News:Kill Cliff® Releases Epic New Product Line – Coffeehouse Quality Cold Brew Coffee in a Can 2Health News:Optimized Care Network Joins First-ever Convenient Healthcare and Pharmacy Collaborative 2Health News:Optimized Care Network Joins First-ever Convenient Healthcare and Pharmacy Collaborative 3Health News:i2i Systems Hires Healthcare Industry Authority Justin L. Neece as Chief Operations Officer 2Health News:Fantastic Team Spirit and Creativity Prevailed at Renew Life “Art de Toilettes” 2
... ... ... , , ... WASHINGTON , Feb. 25 ...
... ... ... ... ...
... ... ... , , , ... ...
... , , ... ... ... ...
... policymakers make reasonable decisions when they have limited ... Charles F. Manski explores in his new paper, ... paper is published online by the Proceedings ... at http://www.pnas.org/content/early/2010/02/05/0915009107.full.pdf+html . "Let,s say you,re ...
... by Johns Hopkins say they have identified the mechanisms rooted ... of schizophrenia and the reason symptoms don,t develop until young ... gene known as DISC1, whose mutant form was first identified ... and related mental disorders. The findings could lead to new ...
Cached Medicine News:Health News:NORD Calls FDA Action 'An Important Advance for Patients' 2Health News:NORD Calls FDA Action 'An Important Advance for Patients' 3Health News:LodgeNet Interactive Names Frank P. Elsenbast As Next Chief Financial Officer 2Health News:LodgeNet Interactive Names Frank P. Elsenbast As Next Chief Financial Officer 3Health News:LodgeNet Interactive Names Frank P. Elsenbast As Next Chief Financial Officer 4Health News:NSBA Implores Congress to Act on Health Care Reform 2Health News:NSBA Implores Congress to Act on Health Care Reform 3Health News:Approval of Kansas Smoke-Free Legislation Is Historic Win for Health 2Health News:Approval of Kansas Smoke-Free Legislation Is Historic Win for Health 3Health News:Approval of Kansas Smoke-Free Legislation Is Historic Win for Health 4Health News:Approval of Kansas Smoke-Free Legislation Is Historic Win for Health 5Health News:How can policymakers cope with ambiguity? 2Health News:Why symptoms of schizophrenia emerge in young adulthood 2Health News:Why symptoms of schizophrenia emerge in young adulthood 3
(Date:8/5/2015)...  GSI Group Inc. (NASDAQ: GSIG ) (the "Company", ... precision motion, and vision technologies to original equipment manufacturers in ... for the second quarter of 2015.Financial HighlightsThree Months Ended(In millions, ... , $ , 96.5 $ ... $ , 10.3 $ , ...
(Date:8/5/2015)... 2015  Innovative therapies that transform quickly progressing, ... – into manageable, chronic conditions offer great hope ... however, they present pharmaceutical companies with unusual drug ... and marketing decisions based on a patient population ... new methods of collecting and analyzing complex clinical, ...
(Date:8/5/2015)... WESTLAKE VILLAGE, Calif. , Aug. 5, ... and KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH ) today ... agreement with respect to Allergan,s pending acquisition of KYTHERA ... agreement amends and restates the original merger agreement entered ... amended on July 1, 2015. Logo - ...
Breaking Medicine Technology:GSI Group Announces Financial Results for the Second Quarter of 2015 2GSI Group Announces Financial Results for the Second Quarter of 2015 3GSI Group Announces Financial Results for the Second Quarter of 2015 4GSI Group Announces Financial Results for the Second Quarter of 2015 5GSI Group Announces Financial Results for the Second Quarter of 2015 6GSI Group Announces Financial Results for the Second Quarter of 2015 7GSI Group Announces Financial Results for the Second Quarter of 2015 8GSI Group Announces Financial Results for the Second Quarter of 2015 9GSI Group Announces Financial Results for the Second Quarter of 2015 10GSI Group Announces Financial Results for the Second Quarter of 2015 11GSI Group Announces Financial Results for the Second Quarter of 2015 12GSI Group Announces Financial Results for the Second Quarter of 2015 13GSI Group Announces Financial Results for the Second Quarter of 2015 14GSI Group Announces Financial Results for the Second Quarter of 2015 15GSI Group Announces Financial Results for the Second Quarter of 2015 16GSI Group Announces Financial Results for the Second Quarter of 2015 17GSI Group Announces Financial Results for the Second Quarter of 2015 18GSI Group Announces Financial Results for the Second Quarter of 2015 19GSI Group Announces Financial Results for the Second Quarter of 2015 20GSI Group Announces Financial Results for the Second Quarter of 2015 21GSI Group Announces Financial Results for the Second Quarter of 2015 22GSI Group Announces Financial Results for the Second Quarter of 2015 23GSI Group Announces Financial Results for the Second Quarter of 2015 24GSI Group Announces Financial Results for the Second Quarter of 2015 25GSI Group Announces Financial Results for the Second Quarter of 2015 26New analytics improve pharmaco strategic decision-making for some deadly diseases 2New analytics improve pharmaco strategic decision-making for some deadly diseases 3Allergan and KYTHERA Announce that Pending Transaction will now be for All-Cash Consideration 2Allergan and KYTHERA Announce that Pending Transaction will now be for All-Cash Consideration 3Allergan and KYTHERA Announce that Pending Transaction will now be for All-Cash Consideration 4Allergan and KYTHERA Announce that Pending Transaction will now be for All-Cash Consideration 5Allergan and KYTHERA Announce that Pending Transaction will now be for All-Cash Consideration 6Allergan and KYTHERA Announce that Pending Transaction will now be for All-Cash Consideration 7Allergan and KYTHERA Announce that Pending Transaction will now be for All-Cash Consideration 8
... ORLANDO, Florida and MELBOURNE, Australia, November 14, 2011 ... Mesenchymal Precursor Cell (MPC) product for cardiovascular diseases, was safe ... responses to donor cells , , ... events (MACE) in patients with congestive heart failure over a ...
... Fla., Nov. 14, 2011 Patients ... stroke and blood clots, failed to remain on the treatment ... according to a study presented at the American Heart Association,s ... The research conducted by Medco Research Institute™, a subsidiary ...
Cached Medicine Technology:Positive Results from Phase 2 Trial of Mesoblast's Adult Stem Cell Therapy Presented at the American Heart Association Annual Meeting 2Positive Results from Phase 2 Trial of Mesoblast's Adult Stem Cell Therapy Presented at the American Heart Association Annual Meeting 3Positive Results from Phase 2 Trial of Mesoblast's Adult Stem Cell Therapy Presented at the American Heart Association Annual Meeting 4Medco Research Institute Study Shows Some Patients Discontinue New Anticoagulant Drug Early, Which May Increase Stroke Risk 2Medco Research Institute Study Shows Some Patients Discontinue New Anticoagulant Drug Early, Which May Increase Stroke Risk 3Medco Research Institute Study Shows Some Patients Discontinue New Anticoagulant Drug Early, Which May Increase Stroke Risk 4
... the pioneers of surgical lighting, including ... automatic reserve bulb, an integrated surgical ... sets the standard for advanced lighting ... our latest generation surgical light ...
... SimpliCT® is an interventional guidance device ... significantly improve the accuracy of computed ... to improving accuracy, SimpliCT® also has ... of CT-guided puncture procedures including biopsies ...
Flat tip, bare fiber, no cooling, polished SMA 905, 3 meters long. Sold in boxes of five. Each part is individually packaged in sterile Tyvek bags....
Get YAG laser performance from your diode laser. Our proprietary NA shift technology offers efficient coupling of low divergence fiber to high divergence lasers...
Medicine Products: